Metformin pathways: pharmacokinetics and pharmacodynamics
about
The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theoryConsumption of clarified grapefruit juice ameliorates high-fat diet induced insulin resistance and weight gain in miceDeciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin ActionGenomic Characterization of Metformin Hepatic ResponseUsing EHR-Linked Biobank Data to Study Metformin Pharmacogenomics.Metformin pharmacogenomics: current status and future directions.Metformin pharmacogenomics: biomarkers to mechanisms.An update on the pharmacogenomics of metformin: progress, problems and potential.Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.Diabetes treatment in patients with renal disease: Is the landscape clear enough?Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands.Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus.Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosisClinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.Metformin - For the dermatologist.The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersThe Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.Potential applications for biguanides in oncologyVariation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo.Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.The pharmacogenetics of type 2 diabetes: a systematic review.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Advances in epilepsy treatment: lacosamide pharmacokinetic profile.Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects.Role of organic cation transporters in drug-drug interaction.Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride.Using Personalized Medicine in the Management of Diabetes Mellitus.Metformin Accelerates Glycolytic Lactate Production in Cultured Primary Cerebellar Granule Neurons.Metformin and pancreatic cancer: Is there a role?Metformin: A Hopeful Promise in Aging Research.Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.The antidiabetic drug metformin decreases mitochondrial respiration and tricarboxylic acid cycle activity in cultured primary rat astrocytes.Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm.A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.Association between the synonymous variant organic cation transporter 3 (OCT3)-1233G>A and the glycemic response following metformin therapy in patients with type 2 diabetes.
P2860
Q26780223-F7CB7A6F-CD45-4D15-AD14-7DC69E2D8634Q28543598-9AFBE433-3B4D-419B-BE83-700E06CB35AAQ28548411-B82574FA-1D60-4D54-97E8-20E1C5F5BEF5Q28554592-EFA2453C-1268-451F-827B-82351F98DB1CQ30955177-E314E0F0-7540-46AD-93F3-444313BF6611Q33959731-A2FD794A-30AE-4D03-B325-862CA5A23F79Q33959783-4621D832-0C47-4332-9F2A-BCDD169FB871Q34003050-538516EA-33E8-4667-8D4C-DFEF8A256F01Q34025097-0F043D2A-7F81-4A32-B367-0C0A4D10E79FQ34068430-DC6A244F-0626-4B77-8951-65BCC8A8A111Q34224429-89CE1D33-279F-4449-879B-6087D86F56D5Q34245062-3DF99663-E58E-424B-88DF-42DFB6CD133EQ35023752-ED9E1899-85F5-40E0-9965-6077675C99E3Q35100131-225F414D-6988-4915-AAD1-1B246C132344Q35114963-3FCFD773-4CF5-433D-B335-DD80DFAA61EFQ36240156-29B8FA7C-C152-48B1-9EF3-D8599E050269Q36651435-FB377A99-5D3D-411D-886C-DE14AC3A420CQ36689589-4BEAFCE6-1DF5-4502-A4D1-D60C346F1174Q36924379-0A251C72-9243-482F-9537-3D852D186A19Q37071977-1C20BA9D-0E20-4036-BB6B-1559BDBE3A0CQ37123877-1F193C40-3A93-4CDF-ABC1-9165765F11BDQ37222650-DDAC6928-75F7-4757-8D8B-7856A1796973Q37272785-A146E389-6B7E-470F-845A-BB8300C7BC4BQ37583856-7B9BC991-882E-42F3-ACBC-6D60F00AC7B9Q37597017-A2704529-3C86-4514-9A9E-7F202AE33952Q38078436-464FF84C-918E-4717-B112-A955CF374F18Q38244248-17003CD2-A0DA-4EDE-A4C7-A01C6E62F805Q38419169-6D8C552A-6AC0-4D92-97C8-6BD7EE545009Q38553282-C33B91C1-A718-4F37-A25E-4AEDFF5FFDD5Q38590960-23FD47E9-448A-4867-A26C-5DEAE38DC724Q38666166-F58C2AAB-840D-49C2-927C-0EAD6A6CC15BQ38688703-562EE9AF-C139-4646-8865-3A86181EF279Q38689022-01807DA8-4652-4990-B1C3-3B1EA5D8974FQ38756907-3579179F-2AD9-47AF-B17E-ABB96ECECFD2Q38851414-41356079-CF42-4578-89AD-07C558CEF9DFQ38896048-A5BB9458-A6D7-482D-9CDD-DD81860B7435Q38973866-32440BF4-0B6C-4C18-A5B2-4F129FDB4444Q39247550-64BF334F-1F49-46CE-A572-CE62202932AEQ39602527-BD83B42E-1E8C-49D1-B05D-8DE1422821FAQ40251170-61C74C23-7D3B-4D72-BF14-B57A92B97C57
P2860
Metformin pathways: pharmacokinetics and pharmacodynamics
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Metformin pathways: pharmacokinetics and pharmacodynamics
@en
type
label
Metformin pathways: pharmacokinetics and pharmacodynamics
@en
prefLabel
Metformin pathways: pharmacokinetics and pharmacodynamics
@en
P2093
P2860
P1476
Metformin pathways: pharmacokinetics and pharmacodynamics
@en
P2093
Kathleen M Giacomini
Srijib Goswami
Teri E Klein
P2860
P304
P356
10.1097/FPC.0B013E3283559B22
P50
P577
2012-11-01T00:00:00Z